Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
NOA LIFT · 1 trial · 1 indication
The NLFSS is a validated 5-point scale used to assess the severity of nasolabial folds, where higher scores indicate more severe folds.
An adverse event (AE) is defined as any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product which does not necessarily have a causal relationship with this treatment.
| Arm | Type | Description |
|---|---|---|
| NOA LIFT | EXPERIMENTAL | Participants will receive initial treatment with NOA LIFT injected into the nasolabial folds. Optional touch-up treatment may be administered at Day 31 if optimal aesthetic correction has not been achieved. |
| JUVÉDERM VOLIFT With Lidocaine | ACTIVE_COMPARATOR | Participants will receive initial treatment with JUVÉDERM VOLIFT with Lidocaine injected into the nasolabial folds. Optional touch-up treatment may be administered at Day 31 if optimal aesthetic correction has not been achieved. |
| Name | Type | Description |
|---|---|---|
| NOA LIFT | DRUG | Injection |
| JUVÉDERM VOLIFT with Lidocaine | DRUG | Injection |
Inclusion Criteria: \- Moderate (2) or Severe (3) on the 5-point Nasolabial Fold Severity Scale (NLFSS) for each nasolabial fold (NLF) on evaluator live assessment (both sides must qualify and have the same score) Exclusion Criteria: * Current cutaneous or mucosal inflammatory or infectious proce...
NOA LIFT is an investigational small molecule being studied for the correction of nasolabial folds in adults. It is currently in Phase 3 clinical development and is not yet approved by regulatory authorities.
NOA LIFT is being developed by AbbVie Inc., a biopharmaceutical company traded on the New York Stock Exchange under the ticker ABBV.
NOA LIFT is in Phase 3 clinical development. It is an investigational drug and has not been approved by the FDA or other regulatory agencies. A Phase 3 trial is currently recruiting participants.
NOA LIFT is being studied in a Phase 3 clinical trial with the identifier NCT07794878. This randomized, double-blind, active-controlled study is assessing adverse events and effectiveness compared to JUVÉDERM VOLIFT With Lidocaine for the correction of nasolabial folds in adults. The trial is recruiting 288 participants in China.
NOA LIFT is not the same as JUVÉDERM VOLIFT. In a Phase 3 clinical trial, NOA LIFT is being compared directly against JUVÉDERM VOLIFT With Lidocaine to assess its effectiveness and safety for correcting nasolabial folds.